CCL2 and neoplasm: In syngeneic and intracranial xenograft mouse models with GL261 glioma, administration of an anti-CCL2 antibody could block recruitment and decrease the number of both MDSCs and TAMs in the TME, leading to prolonged survival of tumor-bearing mice [118,119].